{
    "clinical_study": {
        "@rank": "122557", 
        "arm_group": [
            {
                "arm_group_label": "Antidepressant", 
                "arm_group_type": "Experimental", 
                "description": "Fluoxetine"
            }, 
            {
                "arm_group_label": "Antipsychotic", 
                "arm_group_type": "Active Comparator", 
                "description": "Aripiprazole"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, controlled pilot study comparing the antidepressant fluoxetine with\n      the second generation antipsychotic aripiprazole in approximately 10 subjects aged 12-25 at\n      risk for developing psychosis.\n\n      Our primary hypotheses are that compared to aripiprazole, fluoxetine will be better\n      tolerated and will lead to greater improvement in symptoms at the end of 6 months of\n      treatment."
        }, 
        "brief_title": "The Role of Antidepressants or Antipsychotics in Preventing Psychosis", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Psychotic Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Psychotic Disorders", 
                "Mental Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  12-25 years of age (inclusive)\n\n          -  Able to understand and speak English\n\n          -  Have at least one sub-threshold positive psychotic symptom that is moderate,\n             moderately severe, or severe\n\n        Exclusion Criteria:\n\n          -  Lifetime diagnosis of an Axis I psychotic disorder: schizophreniform disorder;\n             schizophrenia; schizoaffective disorder; bipolar disorder; or major depression with\n             psychotic features\n\n          -  Current psychosis\n\n          -  Current diagnosis of Major Depressive Disorder, single episode or recurrent, severe\n             without psychotic features\n\n          -  Lifetime diagnosis of substance abuse or dependence (excluding nicotine)\n\n          -  Current stimulant treatment\n\n          -  Any significant medical condition that contra-indicates treatment with either\n             aripiprazole or fluoxetine, including history of neurological, neuroendocrine or\n             other medical condition known to affect the brain\n\n          -  Estimated intelligence quotient < 70"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724372", 
            "org_study_id": "12-094"
        }, 
        "intervention": [
            {
                "arm_group_label": "Antidepressant", 
                "intervention_name": "Antidepressant", 
                "intervention_type": "Drug", 
                "other_name": "Fluoxetine"
            }, 
            {
                "arm_group_label": "Antipsychotic", 
                "intervention_name": "Antipsychotic", 
                "intervention_type": "Drug", 
                "other_name": "Aripiprazole"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antidepressive Agents", 
                "Fluoxetine", 
                "Aripiprazole", 
                "Antipsychotic Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2014", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of Antidepressants or Antipsychotics in Preventing Psychosis", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare fluoxetine and aripiprazole on the likelihood of and time to symptomatic improvement.", 
            "measure": "Attenuated positive, negative and general psychiatric symptoms", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724372"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare the effect of fluoxetine and aripiprazole on social and role functioning and subjective well-being in individuals at risk for schizophrenia.", 
                "measure": "Social and role functioning", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To compare aripiprazole and fluoxetine on time to all-cause discontinuation or need to add another psychiatric medication.", 
                "measure": "Time to all-cause discontinuation.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To compare aripiprazole and fluoxetine on the presence of associated rates of adverse effects.", 
                "measure": "Adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "St. Luke's-Roosevelt Hospital Center", 
        "sponsors": {
            "collaborator": {
                "agency": "The Zucker Hillside Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "St. Luke's-Roosevelt Hospital Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}